Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics


Milestone Pharmaceuticals Inc. (MIST): $3.83

-0.07 (-1.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MIST Stock Price Chart Interactive Chart >

Price chart for MIST

MIST Price/Volume Stats

Current price $3.83 52-week high $9.85
Prev. close $3.90 52-week low $3.10
Day low $3.72 Volume 130,500
Day high $4.00 Avg. volume 171,907
50-day MA $3.59 Dividend yield N/A
200-day MA $5.56 Market Cap 131.32M

Milestone Pharmaceuticals Inc. (MIST) Company Bio


Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.


MIST Latest News Stream


Event/Time News Detail
Loading, please wait...

MIST Latest Social Stream


Loading social stream, please wait...

View Full MIST Social Stream

Latest MIST News From Around the Web

Below are the latest news stories about MILESTONE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIST as an investment opportunity.

Milestone Pharmaceuticals GAAP EPS of -$0.31, revenue of $3.5M

  • Milestone Pharmaceuticals press release (NASDAQ:MIST): Q4 GAAP EPS of -$0.31.
  • Revenue of $3.5M.
  • As of December 31, 2022, Milestone had cash, cash equivalents, and short-term investments of $64.6 million, compared to $114.1 million as of December 31, 2021, and 34.3 million 
  • General and administrative expense for the fourth quarter of 2022 was $4.1 million, compar...

    Seeking Alpha | March 29, 2023

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a clinical and corporate update.

Yahoo | March 29, 2023

Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a $125 million strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates ("RTW"). Proceeds from this tailored financing, together with $64.6 million of cash, cash equivalents and short-term investments as of December 31, 2022, are expected to fund

Yahoo | March 28, 2023

Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced significant progress in clinical and regulatory activities for etripamil, the Company's investigational calcium channel blocker that is administered by patients outside of the healthcare setting to treat paroxysmal supraventricular tachycardia (PSVT).

Yahoo | March 6, 2023

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the following investor conferences:

Yahoo | February 28, 2023

Read More 'MIST' Stories Here

MIST Price Returns

1-mo 21.97%
3-mo -3.28%
6-mo -58.32%
1-year -40.34%
3-year 108.15%
5-year N/A
YTD -3.28%
2022 -39.54%
2021 -2.24%
2020 -58.15%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7563 seconds.